Endocrinology

The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.

Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.

Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.

Your daily dose of clinical news you may have missed.

AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.

Your daily dose of clinical news you may have missed.

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.

Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.

In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .

The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.

The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.

In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.

Your daily dose of clinical news you may have missed.

The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.

The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.

Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.

KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.

ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.

Your daily dose of clinical news you may have missed.

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

Your daily dose of clinical news you may have missed.

ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.